

KEEPING KIDS IN TUNE



Fennec Pharmaceuticals is a biotechnology company focused on the development of Sodium Thiosulfate for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients.

Investment Highlights

- ❖ US Orphan Drug Designation (7.5 years market exclusivity)
 - Potential for European Market Exclusivity for Pediatric Use (10 years)
- ❖ Completed enrollment of two Phase 3 trials
- ❖ COG Phase 3 trial achieved primary endpoint for hearing
 - Achieved primary efficacy endpoint of greater than 50% improvement in hearing
- ❖ SIOPEL 6 Phase 3 trial reported no difference in Event Free Survival and Overall Survival at 2 years for cisplatin vs. cisplatin + STS with no evidence of tumor protection
 - Efficacy results (primary endpoint of hearing loss) expected in 2017 when all children have reached 3.5 years of age
 - The interim results of the first 68 patients achieving centrally reviewed pure tone audiometry at or above 3.5 years of age were encouraging
- ❖ Significant unmet medical need with no approved treatment on market or in development
- ❖ Well positioned to initiate discussions with US & European regulators once hearing data is available from SIOPEL 6

Recent News

- 12/1/16 Lancet Oncology Publication of Children's Oncology Group Study of Sodium Thiosulfate
- 6/6/16 SIOPEL 6 Study shows no difference in Event Free Survival and Overall Survival at 2 years for cisplatin vs. cisplatin + STS with no evidence of tumor protection
- 5/16/16 Fennec announces second closing USD\$5.0 million private placement of common shares by Essetifin (f/k/a Sigma Tau Finanziaria)
- 4/8/16 Fennec announces USD\$5.0 million private placement of common shares by Sigma Tau Finanziaria
- 12/9/15 Fennec announces new Chairman of the Board Khalid Islam
- 1/5/15 Fennec announces completion of patient enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
- 12/3/14 Fennec announces USD\$2.2 million private placement
- 6/2/14 Fennec announces COG Study ACCL0431 Phase 3 Clinical Trial for Sodium Thiosulfate meets primary endpoint for prevention of cisplatin-induced hearing loss in children

About the Company:

TSX	FRX
OTCQB	FENCF
Recent market price ¹	USD\$1.80
Shares Outstanding	13.6
Market capitalization ¹	USD\$24.5
Cash ²	USD\$4.5 million
Cash runway	Q1 2018
Debt	\$0

¹ November 14, 2016

Board of Directors

Dr. Khalid Islam

Chairman of Board, Chairman and CEO at Gentium S.p.A. - sold to Jazz Pharma for \$1 billion

Dr. Marco Brughera

Director, CEO and Global Head of Sigma Tau Rare Disease. Previously successfully out-licensed Defibrotide US rights to Jazz Pharma to Baxalta for \$1 billion.

Adrian Haigh

Director, Currently SVP and General Manager PTC Therapeutics. Previously COO at Gentium S.p.A. - sold to Jazz Pharma for \$1 billion.

Chris Rallis

Director, Previously President & COO of Triangle Pharmaceuticals - sold to Gilead for \$500 million.

Rosty Raykov, CEO & Director

CONTACT

Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals
9196365144
rraykov@fennecpharma.com
www.fennecpharma.com

